Founder
Founder
PhD
Distinguished Experts, Chair Professor
Professor LIU earned his Ph.D. in Cell Biology from University of Maryland in College Park, and then did his postdoctoral trainings in Johns Hopkins University School of Medicine, and in California Institute of Technology Division of Biology, USA. He was a tenured full professor in the Institute of Biosciences and Technology, Texas A&M University, and the graduate faculty member in the University of Texas Houston Medical School and UT MD Anderson Cancer Center. After returned to China, Prof. LIU has served as the Dean of Life Sciences for 8 years and has been the Director of Institute of Biomedical Sciences, East China Normal University in Shanghai.
Prof. LIU's research interests focus on cell signaling, cell therapy, gene editing and gene therapy in different diseases. He has published more than 400 research papers in top journals, such as Nature, Science, Nature Biotechnology, Nature Medicine, etc . He has won the first prize of National Science and Technology Progress Award, the first prize of Shanghai Science and Technology Progress Award, and the Shanghai Magnolia Memorial Award.
Founder，Vice Chairman
Founder，Vice Chairman
EMBA of China Europe International Business School and Tsinghua University
Shanghai Minhang Leading Talent
Serial Entrepreneur
XI is a serial entrepreneur with a strong sense of corporate mission and entrepreneurial spirit, emphasizing strategic height and execution. According to his rich experience in operation, management and investment, involving various fields such as biomedicine, great health, and real estate, he currently serves as a core member of the board of directors and the company's decision-making and management committee to drive the development of BRL Medicine.
Co-founder, Vice President
Co-founder, Vice President
PhD , Professor of East China Normal University
Prof. Bing Du is mainly engaged in regulation of tumor immune microenvironment and cancer immune therapy. In recent years, he has published more than 40 SCI papers in the high impact journals such as Science Advances, Cancer Research, Cancer Immunology Research, Cellular & Molecular Immunology and Mucosal Immunology. Meanwhile, he has been authorized more than 10 national invention patents in the past few years.
Co-founder, Vice President
Co-founder, Vice President
PhD , Professor at East China Normal University
Dr. Li is a pioneer in the field of innovative genome editing tool development and CRISPR-based gene therapy. He has published more than 100 research articles in high impact journals, including Nature Biotechnology, Nature Genetics and Nature Cell Biology, and developed several novel editing tools, such as hyCBE and A&C-BEmax.
Chief Medical Officer（CMO）&Chief Operating Officer（COO）
Chief Medical Officer（CMO）&Chief Operating Officer（COO）
Dr. Qian Tan has over 20 years of extensive experience in the pharmaceutical industry and world-top research institutions, with expertise in clinical oncology, precision cancer medicine, cancer genomics, drug development, and clinical trial management. Dr. Tan has led and managed over 100 IND (Investigational New Drug) and IIT (Investigator-Initiated Trial) projects, accumulating global, multi-center, and multi-indication clinical development experience. Dr. Tan hold MD degree from Tianjin Medical University China, master's degree from York University Canada, and PhD degree from the University of Toronto Canada, and completed postdoctoral clinical research fellowship at Stanford University School of Medicine USA. She is also a chair professor of Tianjin Medical University/ Tianjin Cancer center, Shanghai Tech University/Shanghai Clinical Research& Clinical Trial Centre in China and editorial board member for Annals of Translational Medicine and Chinese Journal of Cancer Research.
Co-Partner, Chief Technology Officer(CTO)
Co-Partner, Chief Technology Officer(CTO)
PhD
During his graduate studies, Dr. Binghe Tan focused on the role and mechanism of G protein-coupled receptors and their signaling in the regulation of tumor immunity, exploring the regulation of G protein-coupled receptor-mediated immune cell function and revealing the important roles and mechanisms of macrophages, T cells and other immune cells in the tumor microenvironment. In addition, he has been working on immunotherapy based on the regulation of tumor immune microenvironment. His postdoctoral work focuses on the genericization and functional enhancement of chimeric antigen receptor T cells (CAR-T) using gene editing technology, as well as the development and optimization of engineered T cell preparation processes, with the aim of achieving safety, efficacy and stability goals of universal CART (UCART) in clinical translational applications. He has been published as first author and co-author in Cancer Research, Journal of Immunology, Journal of Biological Chemistry, Science China Life Sciences, Cellular & Molecular Immunology, etc. He has applied for one international invention patent and four Chinese invention patents, one of which has been transferred. He presided over one National Natural Science Foundation of China (NSFC) youth project and participated in several NSFC surface projects as a key technicaldirector.
Co-Partner, Vice President, R&D
Co-Partner, Vice President, R&D
PhD , AssociateProfessor
Jiqin Zhang is focused on the research of gene editing and tumor immune cell therapy. In recent years, he has published more than 20 SCI papers in international journals such as Nature, Nature Communications, Cell Research, Molecular Cancer and Hypertension. As a leader, he has taken charge of two projects of National Natural Science Foundation of China and one project of Shanghai Natural Science Foundation. He also participated in several national and provincial scientific research projects. He has developed an international first non-viral genome specific targeted CAR T cell technology, established the Quikin CART® platform with BRL proprietary intellectual property, providing new strategies to break through the limitations of current CAR T cell therapy.
Co-Partner, Chief Human Resource Officer
Co-Partner, Chief Human Resource Officer
MBA of Wuhan University
CPM® International Certified Property Manager, Certified Instructor of Leadership and Human Resource ManagementNan Xu has worked in human resource management in Dowell Group, Shimao Group, China Resources Group and China Vanke. She has served as HR administrative director of commercial section, assistant HR director of the group, head of HR administration of regional companies, and senior manager of performance management of the group. Has nearly twenty years of experience in organizational development, corporate culture and talent management. Served as a volunteer for the Dima Charity Foundation during the novel coronavirus outbreak, coordinating the procurement of overseas medical supplies. Now she is responsible for the management of human resources, administration and public affairs of the company.
Co-Partner, Vice President, R&D
Co-Partner, Vice President, R&D
Ph.D. in Immunology, Post-Doctoral, East China Normal University
Dr. Na Zhang has long been engaged in the field of cancer immune therapy, especially in cell therapy.
She has developed innovative solid tumor CAR T cell products（Prostate Cancer, Gastric Cancer & Ovarian Cancer et.al.）.
She has hosted National Natural Science Foundation of China & Postdoctoral Foundation, and published several SCI papers in well-known international journals.
Meanwhile, she has been authorized more than 10 national invention patents.
Co-Partner, Director of Marketing & Intellectual Property
Co-Partner, Director of Marketing & Intellectual Property
Anling Huang graduated from East China Normal University with a Master's degree in Biochemistry and Molecular Biology. She won the nomination award of top 30 cutting-edge women in China's intellectual property circle in 2021 and published 3 papers in International Academic Journals. Anling is responsible for company's Intellectual Property & Marketing affairs, and has led the company to obtain honorary titles such as "Shanghai patent pilot enterprise" and "intellectual property management system certification certificate".
Director of R&D
Director of R&D
Dr. Fei Wang holds a PhD in Cell Biology from the Excellence Innovation Center for Molecular Cell Science, Chinese Academy of Sciences, and is primarily responsible for drug development on the Hematopoietic Stem Cell Platform (ModiHSC®) at BRL Medicine, serving as the R&D leader for projects such as BRL-101 and BRL-102. He has published research papers in academic journals such as The EMBO journal and Cell death discovery.
